The Ministry of Health's Revised Implant Subsidy Framework aims to subsidise implants in a fair and sustainable way, through the establishment of the Implant Subsidy List (ISL), formerly known as the Medical Technology Subsidy List (MTSL). Implants are a subset of medical technologies that are placed inside or on the surface of the human body1.

The ISL is a list of implants that will be subsidised when used in Public Healthcare Institutions (PHIs) in accordance with the clinical criteria for subsidy eligibility as stipulated in the ISL. 

At present, the ISL includes implants and some related accessories. The ISL will be expanded progressively over time to include other implants across a wide range of specialities.

1The ISL has referenced the definition of implants from the Health Products Act, Health Products (Medical Devices) Regulation 2010.

Download the Implant Subsidy List (accurate as of 1 December 2023)

Frequently Asked Questions

Expand All | Collapse All

1. What is the purpose of ISL?

The ISL aims to extend subsidies to and encourage the use of clinically effective and cost-effective implants to improve patient outcomes and healthcare resource utilisation.

2. What are the criteria for inclusion in this ISL?

The ISL comprises implants that are evaluated to be safe, clinically effective, and cost-effective in treating the identified clinical indications. HSA registration is a pre-requisite for implants to be considered for listing under the ISL.

3. Who is eligible?

Only subsidised patients may receive subsidies for the implant if they fulfil the clinical criteria for subsidy eligibility as stipulated in the ISL. The amount of subsidies will be based on their citizenship and means-test status, under the prevailing subsidy frameworks in PHIs.

4. Are patients allowed to use implants not listed in the ISL? 

Yes, patients may use implants that are not listed in the ISL, though this is generally not encouraged. However, the use of non-listed implants will not be accorded subsidies and patients can expect to pay more. Patients may approach their public healthcare provider to explore subsidised options listed on the ISL.